BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eijkelenboom A, Tops BBJ, van den Berg A, van den Brule AJC, Dinjens WNM, Dubbink HJ, Ter Elst A, Geurts-Giele WRR, Groenen PJTA, Groenendijk FH, Heideman DAM, Huibers MMH, Huijsmans CJJ, Jeuken JWM, van Kempen LC, Korpershoek E, Kroeze LI, de Leng WWJ, van Noesel CJM, Speel EM, Vogel MJ, van Wezel T, Nederlof PM, Schuuring E, Ligtenberg MJL. Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. Virchows Arch 2019;474:673-80. [PMID: 30888490 DOI: 10.1007/s00428-019-02555-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Tsuriel S, Hannes V, Hasona A, Raz M, Hershkovitz D. Digital PCR-Based Method for Detecting CDKN2A Loss in Brain Tumours. Mol Diagn Ther 2022. [PMID: 36129665 DOI: 10.1007/s40291-022-00610-5] [Reference Citation Analysis]
2 Lassche G, van Helvert S, Eijkelenboom A, Tjan MJH, Jansen EAM, van Cleef PHJ, Verhaegh GW, Kamping EJ, Grünberg K, van Engen-van Grunsven ACH, Ligtenberg MJL, van Herpen CML. Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients. Cancers 2022;14:4156. [DOI: 10.3390/cancers14174156] [Reference Citation Analysis]
3 Ahn M, Mendoza MJL, Pavlakis N, Kato T, Soo R, Kim D, Liam CK, Hsia T, Lee CK, Reungwetwattana T, Geater S, Chan OSH, Prasongsook N, Solomon B, Nguyen TTH, Kozuki T, Yang JC, Wu Y, Mok T, Tan DSW, Yatabe Y. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET alterations in NSCLC: Diagnostic and Therapeutic Considerations. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.07.012] [Reference Citation Analysis]
4 Grafodatskaya D, O'Rielly DD, Bedard K, Butcher DT, Howlett CJ, Lytwyn A, McCready E, Parboosingh J, Spriggs EL, Vaags AK, Stockley TL. Practice guidelines for BRCA1/2 tumour testing in ovarian cancer. J Med Genet 2022:jmedgenet-2021-108238. [PMID: 35393334 DOI: 10.1136/jmedgenet-2021-108238] [Reference Citation Analysis]
5 Boichard A, Lippman SM, Kurzrock R. Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden. J Hematol Oncol 2021;14:201. [PMID: 34857015 DOI: 10.1186/s13045-021-01211-1] [Reference Citation Analysis]
6 Schmitt C, Schulz AA, Winkelmann R, Smith K, Wild PJ, Demes M. Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization. Oncotarget 2021;12:2273-82. [PMID: 34733418 DOI: 10.18632/oncotarget.28092] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Stewart JP, Gazdova J, Darzentas N, Wren D, Proszek P, Fazio G, Songia S, Alcoceba M, Sarasquete ME, Villarese P, van der Klift MY, Heezen KC, McCafferty N, Pal K, Catherwood M, Kim CS, Srivastava S, Kroeze LI, Hodges E, Stamatopoulos K, Klapper W, Genuardi E, Ferrero S, van den Brand M, Cazzaniga G, Davi F, Sutton LA, Garcia-Sanz R, Groenen PJTA, Macintyre EA, Brüggemann M, Pott C, Langerak AW, Gonzalez D; EuroClonality-NGS Working Group. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. Blood Adv 2021;5:3188-98. [PMID: 34424321 DOI: 10.1182/bloodadvances.2020004056] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Roepman P, de Bruijn E, van Lieshout S, Schoenmaker L, Boelens MC, Dubbink HJ, Geurts-Giele WRR, Groenendijk FH, Huibers MMH, Kranendonk MEG, Roemer MGM, Samsom KG, Steehouwer M, de Leng WWJ, Hoischen A, Ylstra B, Monkhorst K, van der Hoeven JJM, Cuppen E. Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics. J Mol Diagn 2021;23:816-33. [PMID: 33964451 DOI: 10.1016/j.jmoldx.2021.04.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
9 de Bitter TJJ, Kroeze LI, de Reuver PR, van Vliet S, Vink-Börger E, von Rhein D, Jansen EAM, Nagtegaal ID, Ligtenberg MJL, van der Post RS. Unraveling Neuroendocrine Gallbladder Cancer: Comprehensive Clinicopathologic and Molecular Characterization. JCO Precis Oncol 2021;5:PO. [PMID: 34036234 DOI: 10.1200/PO.20.00487] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Wei J, Meng P, Terpstra MM, van Rijk A, Tamminga M, Scherpen F, Ter Elst A, Alimohamed MZ, Johansson LF, Stigt J, Gijtenbeek RPG, van Putten J, Hiltermann TJN, Groen HJM, Kok K, van der Wekken AJ, van den Berg A. Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC. Target Oncol 2021;16:215-26. [PMID: 33606136 DOI: 10.1007/s11523-021-00798-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Kroeze LI, de Voer RM, Kamping EJ, von Rhein D, Jansen EA, Hermsen MJ, Barberis MC, Botling J, Garrido-martin EM, Haller F, Lacroix L, Maes B, Merkelbach-bruse S, Pestinger V, Pfarr N, Stenzinger A, van den Heuvel MM, Grünberg K, Ligtenberg MJ. Evaluation of a Hybrid Capture–Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes. The Journal of Molecular Diagnostics 2020;22:757-69. [DOI: 10.1016/j.jmoldx.2020.02.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
12 Beagan JJ, Bach S, van Boerdonk RA, van Dijk E, Thunnissen E, van den Broek D, Weiss J, Kazemier G, Pegtel DM, Bahce I, Ylstra B, Heideman DAM. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment. Lung Cancer 2020;145:173-80. [PMID: 32460198 DOI: 10.1016/j.lungcan.2020.04.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Steeghs EMP, Kroeze LI, Tops BBJ, van Kempen LC, Ter Elst A, Kastner-van Raaij AWM, Hendriks-Cornelissen SJB, Hermsen MJW, Jansen EAM, Nederlof PM, Schuuring E, Ligtenberg MJL, Eijkelenboom A. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. BMC Cancer 2020;20:291. [PMID: 32264863 DOI: 10.1186/s12885-020-06785-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
14 Van Bockstal MR, Agahozo MC, van Marion R, Atmodimedjo PN, Sleddens HFBM, Dinjens WNM, Visser LL, Lips EH, Wesseling J, van Deurzen CHM. Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification. Mol Oncol 2020;14:671-85. [PMID: 32058674 DOI: 10.1002/1878-0261.12650] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]